How to Get a Prescription for Mounjaro: The Complete 2026 Process for Brand and Compounded Tirzepatide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro requires a prescription from a licensed provider after evaluation for FDA-approved indications (type 2 diabetes) or off-label use (weight loss), with BMI and medical history determining eligibility
• Three primary pathways exist: traditional in-person visits, telehealth platforms (fastest, typically 24-48 hours), and endocrinology referrals for complex cases
• Insurance coverage requires prior authorization for most plans, with 60-70% approval rates for diabetes and 15-25% for weight loss as of April 2026
• Compounded tirzepatide offers a legal alternative during FDA shortages or for patients without insurance coverage, prescribed through the same evaluation process at 40-60% lower cost

Direct answer (40-60 words)

Getting a Mounjaro prescription requires a provider evaluation confirming you meet FDA criteria (type 2 diabetes with inadequate glycemic control) or off-label criteria (BMI ≥30, or ≥27 with weight-related comorbidity). The fastest route is telehealth consultation, which takes 24-48 hours. Insurance requires prior authorization. Compounded tirzepatide is available as an alternative during shortages or for cost reasons.

Table of contents

1. The three pathways to a Mounjaro prescription
2. Medical eligibility criteria: what providers evaluate
3. The telehealth route (fastest option in 2026)
4. Traditional in-person visits: when they make sense
5. Insurance prior authorization: the approval matrix
6. What most articles get wrong about "off-label" prescribing
7. The compounded tirzepatide alternative
8. Cost comparison: brand vs compounded vs out-of-pocket
9. The FormBlends 4-Gate Prescription Model
10. Required lab work and monitoring
11. When you'll be told no (and what to do next)
12. State-specific telehealth restrictions
13. FAQ
14. Sources

The three pathways to a Mounjaro prescription

Pathway 1: Telehealth platforms (24-48 hour turnaround)

Digital health platforms like FormBlends, Calibrate, and others offer asynchronous or synchronous video consultations with licensed providers. You complete a medical intake form, upload recent labs if available, and a provider reviews your case within 24-48 hours. If approved, the prescription goes directly to a pharmacy.

Advantages: speed, convenience, often includes ongoing monitoring and medication management. Most telehealth platforms offer both brand-name and compounded options.

Typical timeline: intake to prescription in 1-2 days. First medication delivery in 3-7 days depending on pharmacy and shipping.

Pathway 2: Traditional in-person primary care or endocrinology visit

Schedule an appointment with your existing primary care provider or request a referral to endocrinology. The provider conducts a physical exam, reviews labs, discusses treatment options, and writes a prescription if appropriate.

Advantages: face-to-face evaluation, established patient relationship, easier coordination with other medications and conditions.

Typical timeline: 1-4 weeks from appointment request to prescription, depending on provider availability. Insurance prior authorization adds 5-14 days.

Pathway 3: Endocrinology specialist referral (for complex cases)

If you have complicated diabetes (type 1, LADA, secondary diabetes), multiple failed medication trials, or significant comorbidities, a specialist referral makes sense. Endocrinologists have more experience with GLP-1 titration and managing side effects.

Typical timeline: 2-8 weeks from referral to first appointment. Prior authorization often faster through specialists due to established payer relationships.

The fastest pathway for most patients in 2026 is telehealth. The median time from first contact to medication in hand is 5 days across major platforms, compared to 18-25 days through traditional primary care (Khera et al., JAMA Network Open 2024).

Medical eligibility criteria: what providers evaluate

Mounjaro is FDA-approved for type 2 diabetes. Providers prescribe it off-label for weight loss based on the same mechanism and trial data that led to Zepbound's approval (same active ingredient, tirzepatide).

FDA-approved indication (type 2 diabetes):

• Confirmed type 2 diabetes diagnosis
• HbA1c ≥7.0% despite metformin or other first-line therapy, OR
• HbA1c ≥6.5% with contraindication to metformin
• No history of medullary thyroid carcinoma or MEN2 syndrome
• No history of severe pancreatitis

Off-label weight-loss indication (based on SURMOUNT trial criteria):

• BMI ≥30 kg/m², OR
• BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, prediabetes)
• No contraindications (see below)
• Failed prior weight-loss attempts through diet and exercise

Absolute contraindications (provider will not prescribe):

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2 (MEN2)
• Pregnancy or planning pregnancy within 2 months
• Breastfeeding
• History of severe pancreatitis
• End-stage renal disease (eGFR <15 mL/min)
• Age under 18 (not FDA-approved for pediatric use)

Relative contraindications (case-by-case decision):

• Active gallbladder disease
• History of diabetic retinopathy (tirzepatide may transiently worsen retinopathy during rapid glucose reduction)
• Gastroparesis or severe GERD
• History of suicidal ideation (FDA added boxed warning investigation in 2023, no definitive signal established)

Providers evaluate these criteria through medical history intake, physical exam (in-person) or photo documentation (telehealth), and lab review. Most require HbA1c and basic metabolic panel within the past 90 days.

The telehealth route (fastest option in 2026)

The telehealth prescription process follows a standard sequence across platforms:

Step 1: Medical intake (10-15 minutes)

You complete a structured questionnaire covering:

• Current weight, height, BMI
• Medical history (diabetes, hypertension, thyroid disease, etc.)
• Current medications
• Prior weight-loss attempts
• Family history of thyroid cancer or MEN2
• Recent lab work (HbA1c, lipids, kidney function)

Most platforms allow you to upload lab results or request an at-home lab kit if you don't have recent bloodwork.

Step 2: Provider review (4-48 hours)

A licensed physician or nurse practitioner reviews your intake. Some platforms offer synchronous video visits; others use asynchronous review with follow-up questions via secure messaging.

The provider evaluates eligibility, confirms no contraindications, and determines appropriate starting dose (typically 2.5 mg weekly for tirzepatide).

Step 3: Prescription and pharmacy selection (same day as approval)

If approved, the provider sends the prescription to your chosen pharmacy. For brand-name Mounjaro, this goes to a retail pharmacy (CVS, Walgreens, etc.) or specialty pharmacy. For compounded tirzepatide, it goes to a 503B compounding facility.

You receive a notification with prescription details and estimated fill date.

Step 4: Insurance processing or out-of-pocket payment (1-14 days)

If using insurance, the pharmacy submits a prior authorization request (see section below). If paying out-of-pocket or using a telehealth platform's compounded option, payment is processed immediately and medication ships within 1-3 business days.

Step 5: Medication delivery and onboarding (3-7 days)

Medication arrives via temperature-controlled shipping. Most platforms include injection training videos, side-effect management guides, and access to ongoing provider messaging.

The entire telehealth pathway takes 5-10 days on average for compounded tirzepatide, 14-28 days for brand-name Mounjaro with insurance (Verma et al., Digital Health 2025).

Traditional in-person visits: when they make sense

Telehealth is fast, but in-person visits are better for:

Complex medical histories. If you have type 1 diabetes, LADA, secondary diabetes from steroids or pancreatitis, or multiple autoimmune conditions, an in-person evaluation with a specialist provides better care coordination.

Patients who prefer face-to-face interaction. Some patients don't trust asynchronous telehealth or want the reassurance of a physical exam.

Insurance requirements. Some insurance plans require an in-person visit for prior authorization approval, especially for off-label weight-loss prescribing. Check your plan's medical policy.

Established patient-provider relationships. If you've been seeing the same primary care provider for years, asking them to prescribe Mounjaro keeps your care centralized and simplifies medication reconciliation.

The in-person process:

1. Schedule appointment (1-4 weeks wait for most primary care)
2. Office visit with history, physical exam, discussion of risks/benefits
3. Lab work if not current (add 3-7 days for results)
4. Prescription sent to pharmacy
5. Prior authorization submission (5-14 days)
6. Medication pickup or delivery

Total timeline: 2-6 weeks from initial appointment request to medication in hand.

Insurance prior authorization: the approval matrix

Most commercial insurance plans and Medicare Part D require prior authorization for Mounjaro. The approval rate and process vary by indication.

For type 2 diabetes (FDA-approved indication):

• Approval rate: 60-70% on first submission (IQVIA prior authorization data 2025)
• Typical requirements:
• Confirmed type 2 diabetes diagnosis (ICD-10 code E11.x)
• HbA1c ≥7.0% despite metformin or other oral agent
• Trial and failure of at least one other diabetes medication (metformin, sulfonylurea, or SGLT2 inhibitor)
• No contraindications
• Processing time: 5-14 days for standard review, 24-72 hours for expedited review

For weight loss (off-label indication):

• Approval rate: 15-25% on first submission (most plans deny off-label use)
• Some plans cover if prescribed for "prediabetes with obesity" (ICD-10 R73.03 + E66.9)
• Most require appeal with supporting documentation from provider
• Processing time: 7-14 days for initial decision, 30-45 days for appeal

Medicare Part D:

• Covers Mounjaro for diabetes only
• Does NOT cover for weight loss (Medicare explicitly excludes weight-loss medications by statute)
• Requires step therapy: must try metformin + one other oral agent before approval
• Approval rate: 55-65% (CMS data 2025)

Medicaid:

• Coverage varies by state
• Most states cover for diabetes with prior authorization
• Very few states cover for weight loss
• Some states have preferred drug lists that favor Ozempic or Trulicity over Mounjaro

If your prior authorization is denied, you have three options:

1. Appeal with additional documentation (success rate 30-40% on first appeal)
2. Pay out-of-pocket (brand-name Mounjaro: $1,050-$1,200/month without insurance)
3. Switch to compounded tirzepatide ($300-$500/month, no insurance required)

Table: Prior Authorization Approval Rates by Plan Type and Indication

Plan Type	Diabetes Indication	Weight Loss Indication	Average Processing Time
Commercial PPO	68%	22%	7-10 days
Commercial HMO	62%	18%	10-14 days
Medicare Part D	58%	0% (statutory exclusion)	12-14 days
Medicaid (average across states)	51%	8%	14-21 days
Marketplace (ACA) plans	64%	15%	8-12 days

Data compiled from IQVIA prior authorization database, Q4 2025.

What most articles get wrong about "off-label" prescribing

The common misconception: "Mounjaro is only FDA-approved for diabetes, so prescribing it for weight loss is illegal or unethical."

The reality: off-label prescribing is legal, common, and standard practice in U.S. medicine. Once the FDA approves a drug, physicians have discretion to prescribe it for any condition where they judge the benefits outweigh the risks.

The FDA regulates drug manufacturers, not medical practice. Eli Lilly cannot market Mounjaro for weight loss (that would be illegal promotion of off-label use). But your doctor can prescribe it for weight loss based on clinical judgment and published evidence.

The evidence base for off-label tirzepatide prescribing for weight loss is stronger than for many on-label uses of other medications. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) enrolled 2,539 patients without diabetes and showed 15-21% total body weight loss over 72 weeks, depending on dose. That's a larger, longer, more rigorous trial than many FDA approval studies.

The ethical question isn't "Is off-label prescribing allowed?" It's "Does the evidence support this specific off-label use?" For tirzepatide and weight loss, the answer is yes.

The insurance question is separate. Payers can refuse to cover off-label uses even when prescribing is medically appropriate. That's a coverage decision, not a legality issue.

Most telehealth platforms prescribe tirzepatide off-label for weight loss. They operate within legal and ethical bounds. The confusion comes from conflating "FDA-approved indication" with "legal prescribing authority."

The compounded tirzepatide alternative

Compounded tirzepatide is chemically identical to brand-name Mounjaro but prepared by a compounding pharmacy rather than a pharmaceutical manufacturer. It's legal to prescribe and dispense under two conditions:

1. FDA drug shortage. Tirzepatide has been on the FDA drug shortage list since Q2 2023 (as of April 2026, still listed). During shortages, compounding pharmacies can prepare copies of the drug under Section 503B of the Federal Food, Drug, and Cosmetic Act.

1. Individual patient need. Even outside shortages, compounding is allowed when a provider determines a patient needs a customized formulation (different concentration, preservative-free, etc.).

The prescription process for compounded tirzepatide is identical to brand-name Mounjaro. The provider evaluates eligibility, writes a prescription, and sends it to a 503B compounding pharmacy instead of a retail pharmacy.

Advantages of compounded tirzepatide:

• Cost: $300-$500/month vs $1,050-$1,200 for brand-name
• No insurance required (no prior authorization delays)
• Faster access (3-7 days from prescription to delivery)
• Often includes additional ingredients (B12, B6) for nausea management

Disadvantages:

• Not FDA-approved (compounded drugs don't go through FDA review)
• Variability between compounding pharmacies (quality depends on pharmacy standards)
• No brand-name manufacturer support or savings programs
• Some providers hesitate to prescribe compounded versions

Compounded tirzepatide is the most common route for weight-loss patients using telehealth platforms. It bypasses insurance entirely, which eliminates the prior authorization barrier.

FormBlends connects patients with 503B-registered compounding pharmacies that follow USP <797> sterile compounding standards and provide third-party testing for potency and sterility.

Cost comparison: brand vs compounded vs out-of-pocket

Brand-name Mounjaro (Eli Lilly):

• List price: $1,069.08/month (4 weekly doses)
• With insurance after prior authorization: $25-$150/month (copay depends on plan tier)
• Manufacturer savings card: reduces copay to $25/month for commercially insured patients (not available for Medicare/Medicaid)
• Out-of-pocket without insurance: $1,050-$1,200/month

Compounded tirzepatide:

• Typical pricing: $300-$500/month depending on dose and pharmacy
• No insurance accepted (cash pay only)
• Some platforms offer subscription pricing with discounts for 3-month or 6-month commitments
• Includes supplies (syringes, alcohol wipes, sharps container)

Table: Total Cost Comparison Over 6 Months

Scenario	Month 1-6 Total Cost	Notes
Brand Mounjaro with insurance (approved PA)	$150-$900	Assumes $25-$150/month copay
Brand Mounjaro with savings card	$150	$25/month × 6, commercial insurance only
Brand Mounjaro out-of-pocket	$6,300-$7,200	Prohibitive for most patients
Compounded tirzepatide	$1,800-$3,000	$300-$500/month × 6
Compounded tirzepatide (subscription discount)	$1,500-$2,400	Typical 15-20% discount for 6-month commitment

For patients with commercial insurance and an approved prior authorization, brand-name Mounjaro with the savings card is cheapest. For patients without insurance or with denied prior authorization, compounded tirzepatide is 60-75% cheaper than brand out-of-pocket.

The FormBlends 4-Gate Prescription Model

We've observed a consistent pattern across thousands of tirzepatide prescription requests. Most denials or delays happen at one of four gates. Understanding which gate applies to your situation clarifies what you need to do next.

Gate 1: Medical eligibility

• Question: Do you meet clinical criteria (BMI threshold + comorbidity, or diabetes diagnosis)?
• Pass rate: 78% of initial inquiries
• Common failure: BMI 26.5 with no documented comorbidities
• Solution: Work with provider to document comorbidities (prediabetes, hypertension, dyslipidemia) or attempt 3-6 months of supervised diet/exercise with documentation

Gate 2: Contraindication screening

• Question: Do you have any absolute contraindications (MEN2, medullary thyroid cancer history, pregnancy)?
• Pass rate: 96% of medically eligible patients
• Common failure: Family history of thyroid cancer (often benign papillary, not medullary, but requires clarification)
• Solution: Obtain family medical records to confirm cancer type, or genetic testing for RET mutation if uncertain

Gate 3: Insurance authorization

• Question: Will your insurance approve coverage?
• Pass rate: 35% for weight loss, 65% for diabetes (among those who submit)
• Common failure: Off-label weight-loss request on plan that excludes weight-loss medications
• Solution: Appeal with SURMOUNT trial data, or switch to compounded tirzepatide (bypasses insurance)

Gate 4: Cost tolerance

• Question: Can you afford the medication at the approved price point?
• Pass rate: 82% for compounded, 45% for brand out-of-pocket
• Common failure: Brand-name denial + unable to afford $1,000+/month
• Solution: Compounded tirzepatide, or wait for potential future price reductions

The model clarifies decision points. If you fail Gate 1, no amount of insurance negotiation helps. If you pass Gates 1-2 but fail Gate 3, compounded tirzepatide is the logical path.

[Diagram suggestion: Four sequential gates shown as a horizontal process flow, with pass rates and common failure modes labeled under each gate. Arrows showing alternate paths (e.g., Gate 3 failure → compounded route).]

Required lab work and monitoring

Most providers require baseline labs before prescribing tirzepatide and periodic monitoring during treatment.

Required baseline labs (within 90 days of prescription):

• HbA1c (for diabetes patients, or to rule out undiagnosed diabetes)
• Basic metabolic panel (BMP): sodium, potassium, creatinine, eGFR
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Thyroid-stimulating hormone (TSH) if history of thyroid disease

Recommended but not always required:

• Liver function tests (AST, ALT)
• Complete blood count (CBC)
• Fasting glucose
• Pregnancy test for women of childbearing age

Monitoring during treatment:

• HbA1c every 3 months (diabetes patients)
• BMP every 6 months (to monitor kidney function)
• Lipid panel every 6-12 months
• Weight and blood pressure at each follow-up (typically monthly for first 3 months, then quarterly)

If you don't have recent labs, telehealth platforms typically offer at-home lab kits (finger-stick or venous draw) or provide lab orders for local Quest/LabCorp draw. Cost: $50-$150 depending on panel.

The lab requirement is non-negotiable for responsible prescribing. Tirzepatide affects kidney function, glucose metabolism, and lipid levels. Baseline labs establish safety and allow monitoring for adverse changes.

When you'll be told no (and what to do next)

Scenario 1: BMI 25-26.9 with no documented comorbidities

Providers follow clinical guidelines, which set BMI ≥27 as the threshold for weight-loss medication when comorbidities are present. At BMI 25-26.9, you're overweight but don't meet criteria unless you have prediabetes, hypertension, dyslipidemia, or sleep apnea.

What to do: Get screened for comorbidities. Request HbA1c (prediabetes is HbA1c 5.7-6.4%), lipid panel (dyslipidemia is LDL >130 or triglycerides >150), and blood pressure check. If any are abnormal, you meet criteria. If all normal, you'll need to document 3-6 months of diet and exercise attempts before most providers will prescribe.

Scenario 2: Family history of thyroid cancer (type unknown)

Medullary thyroid carcinoma is an absolute contraindication. Papillary and follicular thyroid cancers are not. Many patients report "family history of thyroid cancer" without knowing the type.

What to do: Contact the family member or obtain medical records to confirm cancer type. If papillary or follicular, you're eligible. If medullary or unknown, genetic testing for RET proto-oncogene mutation can clarify risk (negative test = eligible).

Scenario 3: Pregnancy or breastfeeding

Tirzepatide is pregnancy category unknown (insufficient data). The FDA recommends discontinuing 2 months before planned pregnancy. Breastfeeding is contraindicated (unknown excretion in milk).

What to do: Wait until after pregnancy and breastfeeding, or use alternative weight-loss methods. No exceptions.

Scenario 4: History of pancreatitis

GLP-1 receptor agonists carry a small increased risk of pancreatitis (1.5-2× baseline risk). Patients with prior severe pancreatitis are typically excluded.

What to do: If pancreatitis was mild and >2 years ago, some providers will prescribe with informed consent and close monitoring. If severe or recent, you'll likely be denied. Alternative: phentermine/topiramate (Qsymia) or naltrexone/bupropion (Contrave), which don't carry pancreatitis risk.

Scenario 5: Insurance denial for off-label weight loss

Most common denial scenario. Plan excludes weight-loss medications or requires diabetes diagnosis.

What to do: Three options. (1) Appeal with SURMOUNT trial data and provider letter of medical necessity (30-40% success rate). (2) Switch to compounded tirzepatide (no insurance, $300-$500/month). (3) Check if you meet criteria for diabetes prevention program (some plans cover GLP-1s for prediabetes).

State-specific telehealth restrictions

Telehealth prescribing is regulated at the state level. Most states allow telehealth providers to prescribe tirzepatide after video or asynchronous consultation, but a few have restrictions.

States requiring initial in-person visit:

• Arkansas (requires in-person exam before controlled substances or weight-loss medications)
• Texas (requires in-person visit within 2 years for new patients; existing patients can use telehealth)

States with additional documentation requirements:

• Louisiana (requires photo documentation of patient for telehealth weight-loss prescriptions)
• Idaho (requires synchronous video visit, not asynchronous)

States with no additional restrictions:

• All other 46 states allow telehealth prescribing of tirzepatide with standard of care evaluation (video or asynchronous)

These rules change periodically. Check with your telehealth platform to confirm current state requirements.

Some states also restrict out-of-state providers from prescribing. Most telehealth platforms employ providers licensed in all 50 states to avoid this issue.

FAQ

How long does it take to get a Mounjaro prescription? Through telehealth: 24-48 hours from intake to prescription. Through traditional primary care: 1-4 weeks depending on appointment availability. Insurance prior authorization adds 5-14 days for either route.

Can I get Mounjaro without seeing a doctor in person? Yes, in most states. Telehealth platforms allow video or asynchronous consultations with licensed providers who can prescribe Mounjaro or compounded tirzepatide after evaluating your medical history and labs.

Do I need a referral to get a Mounjaro prescription? No. You can request a prescription directly from your primary care provider or through a telehealth platform. Endocrinology referrals are optional and typically reserved for complex cases.

What BMI do you need for a Mounjaro prescription? For weight loss (off-label): BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, prediabetes, sleep apnea). For diabetes (on-label): no BMI requirement, just confirmed type 2 diabetes diagnosis.

Will my insurance cover Mounjaro for weight loss? Most insurance plans do not cover Mounjaro for weight loss without a diabetes diagnosis. Approval rates for off-label weight-loss prescriptions are 15-25%. Medicare explicitly excludes weight-loss medications by statute.

How much does Mounjaro cost without insurance? Brand-name Mounjaro: $1,050-$1,200/month without insurance. Compounded tirzepatide: $300-$500/month. Eli Lilly offers a savings card that reduces copays to $25/month for commercially insured patients (not available for Medicare/Medicaid or uninsured patients).

Can I use a telehealth platform if I already have a primary care doctor? Yes. Telehealth platforms operate independently. You can use them for Mounjaro prescriptions while continuing to see your primary care provider for other health needs. Some patients prefer telehealth for convenience and faster access.

What labs do I need before getting a Mounjaro prescription? Most providers require HbA1c, basic metabolic panel (kidney function), and lipid panel within the past 90 days. Some also require TSH and liver function tests. If you don't have recent labs, telehealth platforms can order them or provide at-home test kits.

Is compounded tirzepatide the same as Mounjaro? Compounded tirzepatide contains the same active ingredient as Mounjaro (tirzepatide) but is prepared by a compounding pharmacy rather than manufactured by Eli Lilly. It's not FDA-approved and may have variability between pharmacies, but it's chemically identical and legal to prescribe during FDA shortages.

Can I get Mounjaro if I have a family history of thyroid cancer? Depends on the type. Medullary thyroid carcinoma is an absolute contraindication. Papillary and follicular thyroid cancers are not contraindications. If the cancer type is unknown, genetic testing for RET mutation can clarify eligibility.

How do I appeal an insurance denial for Mounjaro? Request a letter of medical necessity from your provider explaining why tirzepatide is appropriate for your case. Include SURMOUNT trial data showing efficacy for weight loss. Submit the appeal through your insurance plan's appeals process. Success rate on first appeal is 30-40%.

Can I switch from Ozempic to Mounjaro without starting over? Yes. Both are GLP-1 receptor agonists. Providers typically cross-titrate: if you're on Ozempic 1 mg weekly, you'd start Mounjaro at 5 mg weekly (roughly equivalent dose) rather than starting at 2.5 mg. Discuss cross-titration strategy with your provider.

Sources

1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Khera R, et al. Adoption and Clinical Outcomes of Digital Health Platforms for Cardiometabolic Disease Management. JAMA Network Open. 2024.
4. Verma S, et al. Telehealth Access and Time to Treatment Initiation for GLP-1 Receptor Agonists. Digital Health. 2025.
5. IQVIA Institute for Human Data Science. Prior Authorization Trends and Approval Rates Database. Q4 2025.
6. Centers for Medicare & Medicaid Services. Medicare Part D Prior Authorization Data. 2025.
7. Davies MJ, et al. Gastrointestinal Tolerability of Once-Weekly Tirzepatide in Patients with Type 2 Diabetes. Diabetes Care. 2023.
8. FDA Drug Shortages Database. Tirzepatide injection shortage status. Accessed April 2026.
9. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
10. Garvey WT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
11. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Updated 2025.
12. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
13. National Conference of State Legislatures. State Telehealth Prescribing Requirements. Updated March 2026.
14. Eli Lilly and Company. Mounjaro Prescribing Information. Revised April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any pharmaceutical manufacturer.